OncLive TV

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.

Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

R. Lor Randall, MD, FACS, discusses how immunodeficient mouse models support mechanistic and therapeutic discovery in rare sarcoma subtypes.

Filippo Pietrantonio, MD, highlights the future directions of assessing amivantamab with or without chemotherapy in patients with colorectal cancer.

Benjamin Herzberg, MD the clinical similarities and key distinctions between sotorasib and adagrasib for KRAS G12C+ NSCLC.

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Rachel N. Grisham, MD, discusses the safety of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Laurence Albiges, MD, PhD, discusses the clinical implications of preliminary efficacy data observed with belzutifan plus lenvatinib in advanced ccRCC.

Evan Y. Yu, MD, discusses the potential utility of AR degradation, mutation inhibition, and suppression for patients with metastatic prostate cancer.

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Neal Shore, MD, FACS, discusses gaps in prostate cancer management and future research directions that may optimize care for high-risk localized disease.

Toon Van Gorp, MD, PhD, discusses the significance of mirvetuximab soravtansine as treatment for FRα-positive, platinum-resistant ovarian cancer.

Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.

Frozen section analysis may be better reserved for high-risk tumor resections, as routine use shows limited benefit and increases cost, survey suggests.

Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.

Axel Merseburger, MD, PhD, discusses AEs associated with real-world treatment discontinuations of avelumab plus axitinib in advanced renal cell carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses the safety of encorafenib plus cetuximab with/without chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

Tanya Gupta, MD, shares factors informing frontline treatment approaches for metastatic hormone receptor–positive, HER2-negative breast cancer.

Andreas M. Kaiser, MD, discusses the benefits of minimally invasive surgery for patients with colorectal cancer.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.